Marksans Pharma Inc. receives USFDA approval for Loperamide Hydrochloride Tablets USP, 2 mg (OTC).

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces the final approval of the Company's wholly owned subsidiary Marksans Pharma Inc.'s Abbreviated New Drug Application (ANDA) for Loperamide Hydrochloride Tablets USP, 2 mg (OTC).

This product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2mg, of Kenvue Brands LLC (Kenvue) NDA - 019860.

Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhea.

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 192.30 as compared to the previous close of Rs. 194.90. The total number of shares traded during the day was 28191 in over 608 trades.

The stock hit an intraday high of Rs. 197.00 and intraday low of 190.90. The net turnover during the day was Rs. 5433785.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 Pharmaceuticals USFDA Approval LoperamideHydrochlorideTablets